Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

Abstract:

:CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopoiesis by normal progenitor cells in vitro. This activity is associated with material which was further purified from CAMAL preparations, and which migrates at 30-35 kDa by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). We now report that material from CAMAL preparations highly enriched for this 30-35 kDa material is stimulatory to in vitro colony formation by progenitor cells from patients with chronic myelogenous leukemia (CML). This stimulatory effect on CML colony formation was observed to be consistent. Colony formation was stimulated in a biphasic fashion; enhancement was seen at low (1 to 10 ng/ml) and high (100 to 200 ng/ml) concentrations of P30-35 CAMAL, but enhancement was reduced or absent at an intermediate concentration of P30-35 CAMAL (10 to 70 ng/ml), and was not observed at P30-35 CAMAL levels above 200 ng/ml, or below 1 ng/ml. The colony types in cultures of CML clinical specimens targetted for enhancement by P30-35 CAMAL were identified. At low concentrations of P30-35 CAMAL primitive colonies were increased, whereas at high concentrations of P30-35 CAMAL, an increase in all colony types was observed. In addition, an increase in the size of some colonies within P30-35 CAMAL-treated cultures was frequently observed. Colony formation by two cell lines derived from the leucocytes of a patient with CML was enhanced by treatment with P30-35 CAMAL in a manner similar to the stimulation observed using primary cells from CML clinical specimens.

journal_name

Leukemia

journal_title

Leukemia

authors

Leitch HA,Buskard N,Levy JG

subject

Has Abstract

pub_date

1993-09-01 00:00:00

pages

1394-401

issue

9

eissn

0887-6924

issn

1476-5551

journal_volume

7

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.

    abstract::t(8;21)(q22;q22) is the most frequently observed karyotypic abnormality associated with acute myeloid leukemia (AML), especially in FAB M2. Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. t(8;21) AML is also frequently associated with additio...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402871

    authors: Nishii K,Usui E,Katayama N,Lorenzo F 5th,Nakase K,Kobayashi T,Miwa H,Mizutani M,Tanaka I,Nasu K,Dohy H,Kyo T,Taniwaki M,Ueda T,Kita K,Shiku H

    更新日期:2003-04-01 00:00:00

  • Pediatric acute myelogenous leukemia cells express IL-6 receptors and are sensitive to a recombinant IL6-Pseudomonas exotoxin.

    abstract::We have studied IL-6 receptor (IL-6R) expression on AML cells from 15 pediatric patients by immunocytochemistry/flow cytometry, reverse-transcription polymerase chain reaction, and Scatchard analysis. High-affinity IL-6R were detected on leukemic cells from 12 (80%) patients. Binding sites per cell ranged from 140 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400914

    authors: Boayue KB,Gu L,Yeager AM,Kreitman RJ,Findley HW

    更新日期:1998-02-01 00:00:00

  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

    abstract::Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.176

    authors: Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

    更新日期:2014-02-01 00:00:00

  • The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.

    abstract::Resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Resistance to this class of drugs may (partly) be reversed by modulating agents, as has been demonstrated in a variety of cell lines. However, it is unknown which modulators may be of clinical benefit in childh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401035

    authors: den Boer ML,Pieters R,Kazemier KM,Janka-Schaub GE,Henze G,Veerman AJ

    更新日期:1998-06-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract::Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2016.299

    authors: Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期:2017-04-01 00:00:00

  • Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

    abstract::JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0638-y

    authors: Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

    更新日期:2020-04-01 00:00:00

  • Bax mutations in cell lines derived from hematological malignancies.

    abstract::Many genes are involved in cell cycle control, DNA repair and induction of cell death. Alterations in these genes have been responsible for the development of cancer as well as for resistance to cancer therapy. Recently, an emerging family of bcl2-like genes has been identified that plays a role in the regulation of c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Meijerink JP,Smetsers TF,Slöetjes AW,Linders EH,Mensink EJ

    更新日期:1995-11-01 00:00:00

  • Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

    abstract::The current study was undertaken to search for differences in the biology of cytogenetic subgroups in patients with de novo acute myeloid leukemia (AML). In addition, factors influencing the metabolism of cytosine arabinoside (araC) as the key agent of antileukemic activity were assessed. Bone marrow aspirates from 91...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402029

    authors: Jahns-Streubel G,Braess J,Schoch C,Fonatsch C,Haase D,Binder C,Wörmann B,Büchner T,Hiddemann W

    更新日期:2001-03-01 00:00:00

  • HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

    abstract::An unambiguous case of Sèzary syndrome associated with the presence of unusual retroviral infection markers is described. The blood smear showed 15% typical Sèzary cells but also rare atypical lymphocytes with convoluted nuclei, evocative of characteristic adult T-cell leukemia (ATL) flower cells. However, the patient...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bazarbachi A,Saal F,Laroche L,Lasneret J,Gessain A,Daniel MT,Périès J

    更新日期:1994-01-01 00:00:00

  • Expression of tie receptor tyrosine kinase in leukemia cell lines.

    abstract::The tie receptor tyrosine kinase mRNA was originally identified as an amplified product in reverse transcription-polymerase chain reaction analysis of human K562 leukemia cell RNA. In situ hybridization analysis revealed that the corresponding mouse gene is expressed predominantly in endothelial cells. We have explore...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Armstrong E,Korhonen J,Silvennoinen O,Cleveland JL,Lieberman MA,Alitalo R

    更新日期:1993-10-01 00:00:00

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    abstract::The 2001 World Health Organization (WHO) treatise on the classification of hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of myeloid neoplasms that includes the four classic myeloproliferative disorders (MPDs)-chronic myelogenous leukemia, polycythemia vera (PV), essential thro...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404955

    authors: Tefferi A,Vardiman JW

    更新日期:2008-01-01 00:00:00

  • Pathogenesis and prevention of HTLV-1-associated diseases.

    abstract::HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

    更新日期:1997-04-01 00:00:00

  • Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells.

    abstract::Multidrug resistance (MDR), a significant impediment to the successful treatment of cancer clinically, has been attributed to the overexpression of P-glycoprotein (P-gp), a plasma membrane multidrug efflux transporter. P-gp maintains sublethal intracellular drug concentrations by virtue of its drug efflux capacity. Th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.76

    authors: Bebawy M,Combes V,Lee E,Jaiswal R,Gong J,Bonhoure A,Grau GE

    更新日期:2009-09-01 00:00:00

  • Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.

    abstract::Osteopontin (OPN) is a multifunctional bone matrix glycoprotein that is involved in angiogenesis, cell survival and tumor progression. In this study we show that human myeloma cells directly produce OPN and express its major regulating gene Runx2/Cbfa1. The activity of Runx2/Cbfa1 protein in human myeloma cells has al...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403976

    authors: Colla S,Morandi F,Lazzaretti M,Rizzato R,Lunghi P,Bonomini S,Mancini C,Pedrazzoni M,Crugnola M,Rizzoli V,Giuliani N

    更新日期:2005-12-01 00:00:00

  • Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia.

    abstract::The number of allogeneic transplants from unrelated donors has grown in the past decade in part because of the expansion of the donor registry size. Patient survival has improved due to the selection of more closely matched donors and the development of effective infection prophylaxis. Relapse-free survival remains li...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401648

    authors: Anasetti C

    更新日期:2000-03-01 00:00:00

  • Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

    abstract::Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.319

    authors: Bernard L,Belisle C,Mollica L,Provost S,Roy DC,Gilliland DG,Levine RL,Busque L

    更新日期:2009-02-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract::The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.10

    authors: Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期:2013-06-01 00:00:00

  • Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with

    abstract::To compare the antileukemic efficacy of idarubicin and mitoxantrone in elderly patients with acute myeloid leukemia (AML) and to evaluate the feasibility of autologous transplantation using PBSC after consolidation in those with a good performance status, 160 patients (median age 69 years), with AML at diagnosis, 118 ...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.leu.2401445

    authors: Archimbaud E,Jehn U,Thomas X,De Cataldo F,Fillet G,Belhabri A,Peaud PY,Martin C,Amadori S,Willemze R

    更新日期:1999-06-01 00:00:00

  • Enhanced AKR leukemogenesis by the dual tropic viruses. I. The time and site of origin of potential leukemic cells.

    abstract::The occurrence of potential leukemia cells (PLC) among bone marrow, spleen, and thymus of AKR mice during the preleukemic period was tested by an in vivo transplantation bioassay. The presence of PLC in 30- and 75-day-old AKR mice was demonstrated mostly among bone marrow cells, less in spleen, and was lacking in thym...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Haran-Ghera N,Peled A,Leef F,Hoffman AD,Levy JA

    更新日期:1987-05-01 00:00:00

  • Cytogenetics and oncogenes.

    abstract::There is abundant evidence that leukemia arise through somatically acquired genetic changes. Familial or congenital predisposition is rarely involved. These genetic changes are often visible as chromosomal aberrations. Molecular analyses of the DNA sequences rearranged in leukemia has demonstrated the presence of cell...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Hagemeijer A

    更新日期:1992-11-01 00:00:00

  • Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.

    abstract::Interleukin-2 (IL-2) is a growth factor which upon binding to high-affinity receptors (IL-2Ralphabetagamma) triggers mitogenesis in T cells. IL-2Ralpha expression is restricted to T cells which have recently encountered antigen, and in healthy individuals the majority (>95%) of peripheral T cells are IL-2Ralpha negati...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402093

    authors: Eriksen KW,Kaltoft K,Mikkelsen G,Nielsen M,Zhang Q,Geisler C,Nissen MH,Röpke C,Wasik MA,Odum N

    更新日期:2001-05-01 00:00:00

  • VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

    abstract::Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.99

    authors: Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

    更新日期:2008-07-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract::Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405087

    authors: San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期:2008-04-01 00:00:00

  • Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines.

    abstract::The Bcr/Abl tyrosine kinase that is expressed from the Philadelphia chromosome protects leukemia cells from apoptosis caused by removal of growth factors or by cytotoxic agents and ionizing irradiation. This resistance to apoptosis is associated with a Bcr/Abl-mediated G2/M delay. Therefore, inhibiting Bcr/Abl signali...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401536

    authors: Sahin MB,Perman SM,Jenkins G,Clark SS

    更新日期:1999-10-01 00:00:00

  • Characterization of acute myeloid leukemia (AML) coexpressing lymphoid markers: different biologic features between T-cell antigen positive and B-cell antigen positive AML.

    abstract::The clinical and biologic characteristics of acute myeloid leukemia (AML) with coexpression of lymphoid-associated antigens (Lym+ AML) were studied from 39 cases who represented 24% of 161 newly diagnosed de novo AML. Twenty-seven cases (16.8%) were positive for the expression of T-cell markers (T+ AML) and 12 (7.5%) ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tien HF,Wang CH,Chen YC,Shen MC,Lin DT,Lin KH

    更新日期:1993-05-01 00:00:00

  • Monoclonal antibodies specific for P-glycoprotein.

    abstract::Multidrug resistance (MDR) is one of the major obstacles to successful cancer chemotherapy. Since P-glycoprotein (P-gp) encoded by the MDR-1 gene plays a key role in MDR, many P-gp-specific monoclonal antibodies (MAbs) have been generated for characterization and analysis of P-gp. Among those antibodies, MRK16 has bee...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400658

    authors: Okochi E,Iwahashi T,Tsuruo T

    更新日期:1997-07-01 00:00:00

  • Identification of a favorable subgroup of patients with generalized immunocytomas by follicular dendritic cells.

    abstract::In the present study, 89 patients with generalized immunocytoma were analyzed retrospectively for the prognostic influence of clinical features and of immunophenotype using bone marrow biopsies. Univariate analysis selected the following variables as significant for survival: age over 60 years (p = 0.021), Rai and Bin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Eisterer W,Hilbe W,Fend F,Ludescher C,Falk M,Thaler J

    更新日期:1995-02-01 00:00:00

  • Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

    abstract::Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. We presently report the results of a trial of mitoxantrone in combination with cytosine arabinoside (ara-C) in patients with refractory or relapsed acute myelocytic leukemia (AML). Fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Paciucci PA,Dutcher JP,Cuttner J,Strauman JJ,Wiernik PH,Holland JF

    更新日期:1987-07-01 00:00:00

  • Expression of p53 in differentiation and apoptosis and its deregulation in tumor cell.

    abstract::The observation that wild type p53 may induce cells to undergo either apoptosis or differentiation raises the question of whether these two events share similar p53-dependent pathways. To evaluate the interrelationship between these two p53-dependent processes, our study focused on the human HL-60, a pro-myelocytic p5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rotter V,Ronen D

    更新日期:1997-04-01 00:00:00

  • Biologic response modifiers in acute lymphoblastic leukemia.

    abstract::Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gribben JG,Cardoso AA,Schultze JL,Nadler LM

    更新日期:1997-05-01 00:00:00